Kristen Fortney is the founder and CEO of BioAge, a biotechnology startup that discovers and develops proprietary drugs to treat aging and associated diseases. Kristen received her PhD from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the American Federation for Aging Research.
She has over 10 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 20 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity, and she is a past recipient of the Glenn Award for Research in Biological Mechanisms of Aging.
 Â
Dr. Nir Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics.
Born in Israel, Dr. Barzilai served as chief medic and physician in the Israel Defense Forces. He graduated from The Ruth and Bruce Rappaport Faculty of Medicine at the Technion-Israel Institute of Technology in Haifa and completed his residency in internal medicine at Hadassah Medical Center in Jerusalem.
Dr. Mannick is Co-Founder and Chief Medical Officer of resTORbio. Prior to joining resTORbio, Dr. Mannick was Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research where she led the clinical program that targets fundamental pathways regulating the biology of aging as a new approach to treating aging-related diseases. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas and a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program
Elizabeth has more than 20 years of experience in broad commercial and development roles including marketing, sales, launch, and access. Elizabeth was previously Vice President of Ophthalmology at Genentech, responsible for the on-market and pipeline molecules.
Prior to that she was General Manager of Roche Norway, Global Head of Commercial Operations and Global Business Unit Head of Established Products at Roche and led the Pricing & Contracting and Strategic Analytics teams at Genentech. She has a background of strategic consulting, healthcare software, and biochemistry bench work at UCSF and Yale. She holds a Masters of Business & Technology from University of New South Wales, Australia, where she was a Fulbright Scholar, and a B.S. in Biology & Management from Yale University. She is actively involved with the HBA and the Springboard Life Sciences Accelerator.